Hydroxychloroquine to reduce steroid use in sarcoidosis
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing clinical trials.
This trial studies whether hydroxychloroquine can control extrapulmonary sarcoidosis (sarcoidosis outside the lungs) using less steroid treatment. It may help people who need systemic therapy for problems such as eyes, skin, bones, joints, nerves, ENT areas, or high calcium levels from sarcoidosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to give informed consent.
- You have sarcoidosis confirmed by a medical tissue test (biopsy) using standard criteria.
- Your sarcoidosis is outside the lungs and is considered non-severe but needs whole-body treatment.
- You must have one of these: non-severe eye, skin, bone, joint, nerve, ENT involvement, or sarcoidosis-related high calcium in blood/urine.
- You must not have recently used other immunosuppressant medicines or steroids (steroids must be stopped at least 3 months), and you must not have taken hydroxychloroquine in the last 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a steroid medication called compound betamethasone for people with newly diagnosed pulmonary sarcoidosis (stage I or II). It may help reduce inflammation and improve symptoms compared to standard prednisone treatment.
This study follows adults with sarcoidosis to see which body “risk signals” (biomarkers) can predict whether the disease will get better or worse. It may help doctors monitor sarcoidosis more closely and choose the right treatment sooner.
This trial tests whether nintedanib, a drug that slows lung scarring, can help people with sarcoidosis-related lung fibrosis. It is for those who still have breathlessness or cough despite stable treatment.
This trial tests if people with stable sarcoidosis can safely lower their corticosteroid dose over time. It may help reduce side effects from long-term steroid use.
This trial tests an experimental drug to see if it can help people with pulmonary sarcoidosis, which affects the lungs. The drug may work by reducing inflammation, and this study will check its safety and effectiveness.
This trial tests an experimental drug called XTMAB-16 for people with sarcoidosis in the lungs, which may also affect other parts of the body. The goal is to see if it helps improve breathing and reduce symptoms.
Hear when a new Sarcoidosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.